To our knowledge, this is the largest clinical trial of WL in older adults with obesity and cardiometabolic disease to track changes in ghrelin and GLP-1 during the intensive phase of treatment and to evaluate these changes as they relate to potential changes in hedonic hunger. Here, GHRL is linked to obesity due to melanocortin 4 receptor deficiency.